Allergan's rapastinel fails to hit key targets in depression trials
admin 7th March 2019 Uncategorised 0Allergan’s rapastinel has failed to hit its primary endpoints in three late-stage studies assessing its potential as an adjunctive treatment for depression.
More: Allergan's rapastinel fails to hit key targets in depression trials
Source: News